摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[4-(2,2,2-Trifluoroethyl)phenyl]methanamine | 1198117-94-0

中文名称
——
中文别名
——
英文名称
[4-(2,2,2-Trifluoroethyl)phenyl]methanamine
英文别名
——
[4-(2,2,2-Trifluoroethyl)phenyl]methanamine化学式
CAS
1198117-94-0
化学式
C9H10F3N
mdl
——
分子量
189.18
InChiKey
ZTEJORXFGZIUAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    26
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • [EN] ISOINDOLINE DERIVATIVES COMPRISING PHENYL GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT DES GROUPES PHÉNYLES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
    申请人:ASTRAZENECA AB
    公开号:WO2009145721A1
    公开(公告)日:2009-12-03
    Compounds of formula I are claimed, (I) wherein R1 is hydrogen, C1-3alkyl, Ci_3alkoxy, cyano, hydroxy or halo; and wherein said Ci^alkyl is optionally substituted by one or more substituents independently selected from hydroxy, Ci^alkoxy andfluoro; and said Ci^alkoxy is optionally substituted by one or morefluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, Ci_4haloalkoxy, halo, Ci_4alkoxy, Ci_4alkyl and C3_7cycloalkyloxy; wherein said C3. γcycloalkyloxy is optionally substituted by one or morefluoro; and R2 and R3 may not both be hydrogen; D is C3_7cycloalkyl or C3_7heterocycloalkyl; and wherein said Cs-jcycloalkyl or Cs- γheterocycloalkyl may optionally be substituted by one or more X*; X4 is halo, Ci_3alkyl, Ci_3alkyl0Ci_3alkyl, Ci_3alkoxy, benzyl, Ci_4alkylsulfonyl, oxo, R4O(C=O), R5(C=O), or C5.6 heteroaryl; wherein said Cisalkyl, CisalkylOCisalkyl, Ci^alkoxy and C i^alkylsulfonyl is optionally substituted by one or more fluoro; R4 is Ci_4alkyl, Ci_4alkyl0Ci_4alkyl, C5_6cycloalkyl, or aryl; R5 is Ci_4alkyl, Ci_4fluoroalkyl or Cs_6 heteroaryl; Li is Ci_4alkylene or a bond; L2 is Ci_3alkylene; with the exception of the compound 2-(cyclohexylmethyl)-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-l-carboxamide; as well as a pharmaceutically acceptable salt, or isomer thereof, or a salt of said isomer. The compounds of the invention are useful in therapy such as pain therapy.
    公式I的化合物被要求,其中R1是氢,C1-3烷基,Ci_3烷氧基,基,羟基或卤素基;其中所述Ci^烷基可以选择性地被一个或多个取代基独立地选择自羟基,Ci^烷氧基和基;所述Ci^烷氧基可以选择性地被一个或多个基取代;m为1或2;R2和R3分别且独立地选择自氢,Ci_4卤代烷基,Ci_4卤代烷氧基,卤素,Ci_4烷氧基,Ci_4烷基和C3_7环烷氧基;其中所述C3. γ环烷氧基可以选择性地被一个或多个基取代;且R2和R3不能同时为氢;D为C3_7环烷基或C3_7杂环烷基;其中所述Cs-j环烷基或Cs-γ杂环烷基可以选择性地被一个或多个X*取代;X4为卤素,Ci_3烷基,Ci_3烷基0Ci_3烷基,Ci_3烷氧基,苄基,Ci_4烷基磺酰基,氧代,R4O(C=O),R5(C=O),或C5.6杂环烷基;其中所述Ci烷基,Ci烷基0Ci烷基,Ci^烷氧基和Ci^烷基磺酰基可以选择性地被一个或多个基取代;R4为Ci_4烷基,Ci_4烷基0Ci_4烷基,C5_6环烷基,或芳基;R5为Ci_4烷基,Ci_4氟烷基或Cs_6杂环烷基;Li为Ci_4烷基或键;L2为Ci_3烷基;除了化合物2-(环己基甲基)-3-氧代-N-[2-(三甲基)苄基]异吲哚啉-1-羧酰胺;以及其药学上可接受的盐,或其异构体的盐。本发明的化合物在治疗中如疼痛治疗中是有用的。
  • [EN] ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT UN GROUPE HÉTÉROCYCLIQUE SUPPLÉMENTAIRE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
    申请人:ASTRAZENECA AB
    公开号:WO2009145718A1
    公开(公告)日:2009-12-03
    Compounds of formula I are claimed, wherein R1is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; wherein C1-3alkyl may optionally be substituted by one or more substituents independently selected from hydroxy, C1-3alkoxy orfluoro; and wherein Ci^alkoxy may optionally be substituted by one or more fluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, C1_4haloalkoxy, halo, C1_4alkoxy, C1_4alkyl and C3_7cycloalkyloxy; and wherein said C3_7cycloalkyloxy may optionally be substituted by one or more fluoro; and whereas both R2 and R3 can not be hydrogen; Het is selected from any one of pyridinyl, pyrazinyl, isoxazolyl, pyrazolyl, indolyl, triazolyl and pyrimidinyl, wherein each such heteroaryl may optionally be substituted by one or more X4; X4 is halo, C1-3alkyl, C1-3alkyl0C1-3alkyl, -CH(CH3)-O-C(CH3)3,C1_4alkoxy, cyano, or hydroxyl, or Ci_2hydroxyalkyl;; and wherein said C1-3alkyl, C 1-3alkylOC1-3alkyl, -CH(CH3)-O-C(CH3)3, or C1_4alkoxy may each optionally be substituted by one or more fluoro; L1 is C1_4alkylene, which may optionally be fluorinated or hydroxylated; and L2 is C1-3alkylene; with the exception of the compounds: 2-[1-(1,5-dimethyl-lH-pyrazol-4-yl)ethyl]-5,7-dimethoxy-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-1-carboxamide; N-(4-fluorobenzyl)-3-oxo-2-(-pyridin-4-yletyl)isoindoline-1-carboxamide and N-(2-chlorobenzyl)-2[2-(1H-indol-3-yl)-1-methyletyl]-3-oxoisoindoline-1-carboxamide; The invention further relates to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    公式I的化合物被要求,其中R1是氢,C1-3烷基,C1-3烷氧基,基,羟基或卤素;其中C1-3烷基可以选择性地被一个或多个取代基取代,这些取代基独立地选自羟基,C1-3烷氧基或基;而C1-3烷氧基可以选择性地被一个或多个基取代;m为1或2;R2和R3分别且独立地选自氢,C1-4卤代烷基,C1-4卤代烷氧基,卤素,C1-4烷氧基,C1-4烷基和C3-7环烷氧基;其中所述的C3-7环烷氧基可以选择性地被一个或多个基取代;而且R2和R3都不能是氢;Het选自吡啶基,吡嗪基,异噁唑基,吡唑基,吲哚基,三唑基和嘧啶基中的任何一种,其中每种这样的杂环烷基可以选择性地被一个或多个X4取代;X4是卤素,C1-3烷基,C1-3烷氧基C1-3烷基,-CH(CH3)-O-C( )3,C1-4烷氧基,基,或羟基,或C1-2羟基烷基;而所述的C1-3烷基,C1-3烷氧基C1-3烷基,-CH( )-O-C( )3,或C1-4烷氧基可以选择性地被一个或多个基取代;L1是C1-4烷基,可以选择性地被化或羟基化;而L2是C1-3烷基;除了以下化合物:2-[1-(1,5-二甲基-1H-吡唑-4-基)乙基]-5,7-二甲氧基-3-氧代-N-[2-(三甲基)苯甲基]异吲哚啉-1-羧酰胺;N-(4-氟苯甲基)-3-氧代-2-(-吡啶-4-基乙基)异吲哚啉-1-羧酰胺和N-(2-氯苯甲基)-2[2-(1H-吲哚-3-基)-1-甲基乙基]-3-氧代异吲哚啉-1-羧酰胺;本发明还涉及含有所述化合物的药物组合物以及所述化合物在治疗中的使用。
  • [EN] ISOINDOLINE DERIVATIVES COMPRISING A CYANO GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS D'ISO-INDOLINE COMPRENANT UN GROUPE CYANO ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
    申请人:ASTRAZENECA AB
    公开号:WO2009145719A1
    公开(公告)日:2009-12-03
    Compounds of formula I are claimed, wherein R1 is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; and wherein said C1-3alkyl is optionally substituted by one or more substituents independently selected from hydroxy, C1_3alkoxy andfluoro; and said C1_3alkoxy is optionally substituted by one or more fluoro; m is 1, 2 or 3; R2 and R3 is each and independently selected from hydrogen, C1-4haloalkyl, C1-4haloalkoxy, halo, C1-4alkoxy, C1-4alkyl and C3_7Cycloalkyloxy; wherein said C3_7cycloalkyloxy is optionally substituted by one or more fluoro; and R2 and R3 may not both be hydrogen; L1 is C1-4alkylene, pentylene, or C3-6 cycloalkylene, wherein said C1-4alkylene, pentylene or C3-6 cycloalkylene may be optionally substituted by one or more X4; X4 is fluoro, C1_3alkyl, C3_7Cycloalkyl, C1_3alkylOCi_3alkyl, C1_3alkoxy, cyano, hydroxy, R4O(C=O)-, R4NR5(C=O)-, R4O(C=O)NR5-, R4NR5(C=O)NR5-, R4(C=O)O-, R4(C=O)NR5-, R4NR5(C=O)O-, R4NR5(C=O)NR5-, C5-6 heteroaryl(C=O), or C5-6 heteroaryl; R4 is C1-4 alkylOC1-4 alkyl, C5-6 cycloalkyl, aryl, or aryl-C1-2 alkyl; R5 is H or methyl; and wherein said C1-3 alkylOC1-3alkyl, C1-3alkoxy and C1-4alkylsulfonyl is optionally substituted by one or more fluoro; L2 is C1-3 alkylene, optionally substituted by one or more X4; as well as pharmaceutically acceptable salt, or isomer thereof, or a salt of said isomer. Compounds of the invention are useful in therapy, such as pain therapy.
    公式I的化合物被声明,其中R1是氢,C1_3烷基,C1_3烷氧基,基,羟基或卤素; 其中所述的C1-3烷基可以选择地被一个或多个独立选择自羟基,C1_3烷氧基和代基的取代基所取代; 所述的C1_3烷氧基可以选择地被一个或多个代基所取代; m为1、2或3; R2和R3分别且独立地选择自氢,C1-4卤代烷基,C1-4卤代烷氧基,卤素,C1-4烷氧基,C1-4烷基和C3_7环烷氧基; 其中所述的C3_7环烷氧基可以选择地被一个或多个代基所取代; R2和R3不能同时为氢; L1为C1-4烷基,戊烷基或C3-6环烷基,其中所述的C1-4烷基,戊烷基或C3-6环烷基可以选择地被一个或多个X4所取代; X4为代基,C1_3烷基,C3_7环烷基,C1_3烷基氧C1_3烷基,C1_3烷氧基,基,羟基,R4O(C=O)-,R4NR5(C=O)-,R4O(C=O)NR5-,R4NR5(C=O)NR5-,R4(C=O)O-,R4(C=O)NR5-,R4NR5(C=O)O-,R4NR5(C=O)NR5-,C5-6杂环芳基(C=O),或C5-6杂环芳基; R4为C1-4烷氧基C1-4烷基,C5-6环烷基,芳基,或芳基-C1-2烷基; R5为H或甲基; 其中所述的C1-3烷氧基C1-3烷基,C1-3烷氧基和C1-4烷基磺酰基可以选择地被一个或多个代基所取代; L2为C1-3烷基,可以选择地被一个或多个X4所取代; 以及药学上可接受的盐,或其异构体,或所述异构体的盐。本发明的化合物在治疗中很有用,如疼痛治疗。
  • [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2012053186A1
    公开(公告)日:2012-04-26
    The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及具有对电压门控通道(如TTX-S通道)具有阻塞活性的芳基酰胺衍生物,用于治疗或预防涉及电压门控通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控通道的这类疾病中使用这些化合物和组合物。
  • Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use
    申请人:Moinet Christophe
    公开号:US20070043095A1
    公开(公告)日:2007-02-22
    The present invention is drawn to compounds of the formula in racemic and enantiomeric form or all combinations of these forms wherein the various substituents are as defined in the application which compounds have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties.
    本发明涉及公式中的化合物,包括外消旋和对映体形式或这些形式的所有组合,其中各种取代基的定义如申请书所述。这些化合物对某些生长抑素受体亚型具有良好的亲和力,并具有有用的药理学性质。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫